ATNF Form 4: Blair Jordan Receives 771,044 Options; Major Voting Proxies Disclosed
Rhea-AI Filing Summary
180 Life Sciences Corp. reported that Director and Chief Executive Officer Jordan Blair received a grant of 771,044 non-qualified stock options on 08/08/2025 under the company’s 2025 Second Supplemental Option Plan with an exercise price of $3.01. The options vested immediately but are not exercisable until stockholder approval of the plan; if approval is not received by 08/08/2026 the options will be cancelled. The options expire on 08/08/2035 and were issued as consideration for services rendered.
The filing shows Mr. Blair’s indirect holdings include 327,576 shares through Blair Jordan Strategy and Finance Consulting Inc. and irrevocable voting proxies covering 43,166, 200,000 and 1,318,000 shares from three parties, where he has voting authority only and no dispositive control or pecuniary interest in those shares.
Positive
- Large option grant of 771,044 non-qualified stock options granted to the CEO (aligns compensation with company performance once exercisable)
- Options vested immediately, providing clear compensation recognition for services rendered
- Voting agreements align significant share voting (43,166; 200,000; 1,318,000) with the Board’s recommendations
Negative
- Options are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan; if not approved by 08/08/2026, options will be cancelled
- Voting proxies do not convey economic ownership; the reporting person expressly has no dispositive control or pecuniary interest in proxied shares
- Potential dilution if options are approved and exercised (771,044 shares underlying options)
Insights
TL;DR: CEO received 771,044 options at $3.01 that vest immediately but require shareholder approval to be exercisable; voting proxies concentrate director voting power.
The option grant of 771,044 non-qualified options at $3.01 is material for executive compensation disclosure and could affect potential dilution if exercised and if shareholder approval is obtained. Immediate vesting accelerates recognition of compensation expense and aligns economic interest timing to the plan approval event. The filing also documents irrevocable voting proxies covering 43,166, 200,000 and 1,318,000 shares that increase the reporting person’s voting influence, although the filing expressly states he has no dispositive or pecuniary interest in those proxied shares.
TL;DR: Governance note — large voting proxies centralize board-aligned control; option exercisability depends on stockholder approval, creating a conditional award.
The three irrevocable voting agreements concentrate voting authority for board-recommended actions while preserving that the reporting person lacks dispositive control or economic ownership of those shares. From a governance perspective, irrevocable proxies can secure short-term director support but do not convey economic alignment. The options’ immediate vesting paired with conditional exercisability pending shareholder approval is a governance mechanism that limits economic transfer until shareholders ratify the plan; failure to obtain approval by 08/08/2026 results in cancellation of the award.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 771,044 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Mr. Jordan owns and controls Blair Jordan Strategy and Finance Consulting Inc. and as such is deemed to beneficially own the securities held by such entity. On February 5, 2025, the Issuer, the Reporting Person and Dr. James Woody, entered into a Voting Agreement, whereby Dr. Woody agreed to vote a total of 43,166 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025, that Dr. Woody has sold all of the shares or the date that the Issuer terminates the Voting Agreement. In order to enforce the terms of the Voting Agreement, Dr. Woody provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 43,166 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 43,166 shares of common stock of the Issuer held by Dr. Woody. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein. On February 21, 2025, the Issuer, the Reporting Person and Dr. Marlene Krauss, entered into a Voting Agreement, whereby Dr. Krauss agreed to vote a total of 200,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to August 21, 2025. In order to enforce the terms of the Voting Agreement, Dr. Krauss provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 200,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 200,000 shares of common stock of the Issuer held by Dr. Krauss. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein. On April 28, 2025, the Issuer, the Reporting Person and Elray Resources, Inc. ("Elray") entered into a Voting Agreement, whereby Elray agreed to vote a total of 1,318,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to April 28, 2026. In order to enforce the terms of the Voting Agreement, Elray provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 1,318,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 1,318,000 shares of common stock of the Issuer held by Elray. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein. The options were granted under the 2025 Second Supplemental Option Plan of the Issuer. The options vested immediately, but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received. If stockholder approval is not received prior to August 8, 2026, the options will be cancelled. Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as an officer of the Issuer.
